Status:
COMPLETED
Cellular Immune Augmentation in Colon and Rectal Cancer
Lead Sponsor:
University of California, Irvine
Conditions:
Colon Cancer
Rectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
While new treatments for metastatic and recurrent colorectal cancer have become available over the past several years, this disease remains incurable with a limited life expectancy from the time of di...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient must have: metastatic, disseminated or recurrent colon or rectal cancer
- Patient to receive weekly or biweekly chemotherapy for at least 4 cycles (4 weeks) Examples include: 5FU or 5FU/leucovorin given once weekly Irinotecan (single agent) given once weekly 5FU/leucovorin/irinotecan given once weekly
- Patient must be able to be taught to administer GM-CSF subcutaneously
- Exclusion criteria:
- Known allergic or other adverse reaction to GM-CSF
- Chemotherapy administration more frequently than bi-weekly
- Pregnant or lactating women
Exclusion
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00257322
Start Date
April 1 2003
End Date
January 1 2007
Last Update
October 31 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chao Family Comprehensive Cancer Center
Orange, California, United States, 92868